Lower HDL-cholesterol levels are associated with increased risk of abdominal aortic aneurysm, highlighting HDL's protective role in AAA progression.
Do HDL-targeted therapies reduce the risk and progression of abdominal aortic aneurysm?
Current evidence supports a protective role for HDL in AAA pathogenesis, highlighting HDL-targeted therapies as promising avenues for future treatment.
Absolute Event Rate: 0% vs 0%
Abstract Purpose of Review This review examines the role of high-density lipoprotein (HDL) in the context of abdominal aortic aneurysm (AAA). It focuses on the correlation between HDL and AAA risk, while also exploring the mechanisms by which HDL may protect against AAA progression. Recent Findings Large epidemiological and genetic studies have consistently shown that lower HDL-cholesterol (HDL-C) levels are associated with an increased risk of AAA. HDL exerts a protective effect against AAA formation through its anti-inflammatory, antioxidant, and endothelial protective functions. Recent therapeutic strategies aimed at augmenting HDL functionality, including synthetic HDL (sHDL) and apolipoprotein A-I (ApoA-I) mimetics, have demonstrated promising results in animal models. Summary Current evidence supports a protective role for HDL in AAA pathogenesis. Strategies aimed to improve or mimic HDL function represent promising avenues for future AAA treatment, emphasizing the need for continued translational research and clinical development.
Catalano et al. (Sat,) reported a other. Lower HDL-cholesterol levels are associated with increased risk of abdominal aortic aneurysm, highlighting HDL's protective role in AAA progression.